Chicago Capital LLC Sells 928 Shares of Axon Enterprise, Inc $AXON

Chicago Capital LLC cut its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 5.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,761 shares of the biotechnology company’s stock after selling 928 shares during the quarter. Chicago Capital LLC’s holdings in Axon Enterprise were worth $12,746,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise in the 1st quarter worth $33,000. Hemington Wealth Management raised its position in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares in the last quarter. Whipplewood Advisors LLC lifted its holdings in shares of Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 27 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in Axon Enterprise in the second quarter worth about $37,000. Finally, NewSquare Capital LLC grew its position in Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,797 shares of Axon Enterprise stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the sale, the insider directly owned 83,485 shares of the company’s stock, valued at $45,017,616.55. The trade was a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Brittany Bagley sold 2,500 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $610.00, for a total value of $1,525,000.00. Following the completion of the sale, the chief financial officer owned 91,092 shares of the company’s stock, valued at $55,566,120. This represents a 2.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 50,540 shares of company stock worth $28,494,638 over the last three months. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Up 4.9%

Shares of AXON opened at $591.16 on Tuesday. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The company has a 50-day moving average of $582.72 and a 200 day moving average of $691.94. The firm has a market capitalization of $46.65 billion, a price-to-earnings ratio of 187.08, a PEG ratio of 17.74 and a beta of 1.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.45 earnings per share. On average, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AXON. Royal Bank Of Canada began coverage on Axon Enterprise in a research note on Monday, November 17th. They issued an “outperform” rating and a $860.00 price objective for the company. UBS Group lowered their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Piper Sandler dropped their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Barclays reduced their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Finally, Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $802.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.